Liraglutide is a long-acting human glucagon-like peptide 1 (GLP-1) analog that was approved by the FDA in 2010 as an adjunct to diet and exercise to improve glycemic control in adults with T2DM [6]. This evidence concerns the gene GCG and type 2 diabetes mellitus.